Stratec Valuation

Is SBSD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SBSD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SBSD (€32.6) is trading below our estimate of fair value (€54.88)

Significantly Below Fair Value: SBSD is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBSD?

Other financial metrics that can be useful for relative valuation.

SBSD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA14.3x
PEG Ratio1.5x

Price to Earnings Ratio vs Peers

How does SBSD's PE Ratio compare to its peers?

The above table shows the PE ratio for SBSD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.9x
NIOX NIOX Group
23x17.1%UK£255.4m
EKF EKF Diagnostics Holdings
25.5xn/aUK£127.7m
SN. Smith & Nephew
35x22.5%UK£8.2b
AMS Advanced Medical Solutions Group
44x23.0%UK£491.1m
SBSD Stratec
39x25.4%€390.2m

Price-To-Earnings vs Peers: SBSD is expensive based on its Price-To-Earnings Ratio (39x) compared to the peer average (32.1x).


Price to Earnings Ratio vs Industry

How does SBSD's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a22.8%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a22.8%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: SBSD is expensive based on its Price-To-Earnings Ratio (39x) compared to the European Medical Equipment industry average (30.3x).


Price to Earnings Ratio vs Fair Ratio

What is SBSD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBSD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SBSD's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SBSD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€32.60
€41.00
+25.8%
14.5%€50.00€31.00n/a6
Nov ’25n/a
€41.00
0%
14.5%€50.00€31.00n/a6
Oct ’25n/a
€43.83
0%
9.2%€50.00€40.00n/a6
Sep ’25n/a
€42.33
0%
7.0%€47.00€40.00n/a6
Aug ’25n/a
€42.33
0%
7.0%€47.00€40.00n/a6
Jul ’25n/a
€42.33
0%
7.0%€47.00€40.00n/a6
Jun ’25n/a
€42.33
0%
7.0%€47.00€40.00n/a6
May ’25n/a
€43.83
0%
12.7%€55.00€40.00n/a6
Apr ’25€39.10
€49.00
+25.3%
14.0%€58.00€40.00n/a6
Mar ’25n/a
€49.00
0%
14.0%€58.00€40.00n/a6
Feb ’25n/a
€49.00
0%
14.0%€58.00€40.00n/a6
Jan ’25n/a
€52.17
0%
8.5%€58.00€44.00n/a6
Dec ’24n/a
€54.00
0%
4.7%€58.00€50.00n/a6
Nov ’24n/a
€54.50
0%
5.1%€58.00€50.00n/a6
Oct ’24n/a
€57.00
0%
6.2%€62.00€52.00n/a6
Sep ’24n/a
€58.67
0%
4.0%€62.00€55.00n/a6
Aug ’24n/a
€59.33
0%
4.4%€62.00€55.00n/a6
Jul ’24n/a
€74.67
0%
11.4%€87.00€62.00n/a6
Jun ’24n/a
€73.67
0%
11.0%€87.00€62.00n/a6
May ’24n/a
€72.83
0%
12.2%€87.00€62.00n/a6
Apr ’24€64.30
€75.33
+17.2%
9.9%€87.00€63.00€39.106
Mar ’24€76.20
€102.00
+33.9%
15.0%€125.00€82.00n/a6
Feb ’24n/a
€102.00
0%
15.0%€125.00€82.00n/a6
Jan ’24n/a
€102.00
0%
15.0%€125.00€82.00n/a6
Dec ’23€86.30
€102.00
+18.2%
15.0%€125.00€82.00n/a6
Nov ’23n/a
€103.83
0%
14.0%€125.00€82.00n/a6

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies